[go: up one dir, main page]

PE20001084A1 - Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas - Google Patents

Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas

Info

Publication number
PE20001084A1
PE20001084A1 PE1999000948A PE00094899A PE20001084A1 PE 20001084 A1 PE20001084 A1 PE 20001084A1 PE 1999000948 A PE1999000948 A PE 1999000948A PE 00094899 A PE00094899 A PE 00094899A PE 20001084 A1 PE20001084 A1 PE 20001084A1
Authority
PE
Peru
Prior art keywords
microadenomas
adhd
parkinson
disease
treatment
Prior art date
Application number
PE1999000948A
Other languages
English (en)
Inventor
Elisa Rose Jackson
Stevin Howard Zor
Stafford Mclean
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20001084A1 publication Critical patent/PE20001084A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE DERIVADOS DE PIRIDO[1,2-a]-PIRAZINA DE FORMULA I, DONDE X ES N o CH; Y ES GRUPO a, b, ENTRE OTROS; Z ES GRUPO c, d, SCH2, OCH2, Y1(CH2)n SUSTITUIDO CON 2 METILO, DONDE n ES 1-2, Y1 ES CH2, NH o NCH3. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: a)UN COMPUESTO QUE SE UNE AL RECEPTOR ALFA 2 ADRENERGICO; b)UN AGENTE AGONISTA DEL RECEPTOR DOPAMINA 2 (D2); c)UN AGENTE AGONISTA DEL RECEPTOR DE SEROTONINA-1A (5HT1A); d)UN VEHICULO FARMACEUTICAMENTE ACEPTABLE; TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE SUNIPETRON. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON, TRASTORNOS DE HIPERACTIVIDAD CON DEFICIT DE ATENCION (ADHD) Y MICROADENOMAS
PE1999000948A 1998-09-21 1999-09-17 Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas PE20001084A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10119198P 1998-09-21 1998-09-21
US10386898P 1998-10-12 1998-10-12

Publications (1)

Publication Number Publication Date
PE20001084A1 true PE20001084A1 (es) 2000-10-18

Family

ID=26798000

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000948A PE20001084A1 (es) 1998-09-21 1999-09-17 Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas

Country Status (38)

Country Link
US (2) US6300329B1 (es)
EP (1) EP1115402A1 (es)
JP (1) JP2002526448A (es)
KR (3) KR20040054752A (es)
CN (1) CN1319013A (es)
AP (1) AP1456A (es)
AR (1) AR029739A1 (es)
AU (1) AU760230B2 (es)
BG (1) BG105445A (es)
BR (1) BR9913975A (es)
CA (1) CA2344670A1 (es)
CO (1) CO5140075A1 (es)
CZ (1) CZ20011006A3 (es)
DZ (1) DZ2894A1 (es)
EA (2) EA200100204A1 (es)
EE (1) EE200100179A (es)
GE (1) GEP20033081B (es)
GT (1) GT199900154A (es)
HN (1) HN1999000146A (es)
HR (1) HRP20010209A2 (es)
HU (1) HUP0103691A3 (es)
ID (1) ID28028A (es)
IL (2) IL141507A0 (es)
IS (1) IS5852A (es)
MA (1) MA26690A1 (es)
MY (1) MY127939A (es)
NO (1) NO20011409L (es)
NZ (1) NZ509855A (es)
OA (1) OA11653A (es)
PA (1) PA8482001A1 (es)
PE (1) PE20001084A1 (es)
PL (1) PL346904A1 (es)
SK (1) SK3592001A3 (es)
TN (1) TNSN99177A1 (es)
TR (2) TR200101357T2 (es)
TW (1) TW518225B (es)
WO (1) WO2000016777A1 (es)
YU (1) YU21701A (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
GB0027020D0 (en) * 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
WO2002102988A2 (en) * 2001-06-18 2002-12-27 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using 5ht-1a agonists
US20030036555A1 (en) * 2001-08-03 2003-02-20 Boehringer Ingelheim Pharma Kg Pramipexole for the treatment of ADHD
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
EP1765075A4 (en) * 2004-06-10 2010-11-10 Mclean Hospital Corp PYRIMIDINES, AS FORM. uridine; IN THE TREATMENT OF PATIENTS WITH MANIC-DEPRESSIVE PSYCHOSIS
EP1784199A4 (en) * 2004-08-11 2010-06-23 Mclean Hospital Corp COMPOUNDS FOR TREATING MARIHUANA DEPENDENCE, DEDUCTION AND CONSUMPTION
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
PE20070523A1 (es) 2005-09-12 2007-06-28 Wyeth Corp Formulacion de liberacion sostenida del glucuronato de (8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona
GT200600416A (es) 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008083442A1 (en) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Method for formulating combination medications for adhd
CN101318020B (zh) * 2007-06-06 2011-09-28 四川科瑞德制药有限公司 抗焦虑或/和抗抑郁的药物组合物及用途
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders
CN104892589A (zh) 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
WO2016186968A1 (en) 2015-05-15 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating motor disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX19222A (es) * 1989-01-23 1993-12-01 Pfizer Agentes ansioliticos bis-aza-biciclicos
WO1992000075A1 (en) * 1990-06-29 1992-01-09 Pfizer Inc. Pyridopyrazine derivatives for treating substance abuse and addiction
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
GB9408084D0 (en) * 1994-04-23 1994-06-15 Boots Co Plc Medical treatment
ES2163506T3 (es) * 1994-06-14 2002-02-01 Pfizer Derivados de bencimidazolona con actividad dopaminergica central.
US5877183A (en) * 1996-06-06 1999-03-02 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.

Also Published As

Publication number Publication date
IL164839A0 (en) 2005-12-18
MY127939A (en) 2007-01-31
AU760230B2 (en) 2003-05-08
ID28028A (id) 2001-05-03
TNSN99177A1 (fr) 2005-11-10
AP2001002102A0 (en) 2001-03-31
CZ20011006A3 (cs) 2001-09-12
JP2002526448A (ja) 2002-08-20
US6300329B1 (en) 2001-10-09
HN1999000146A (es) 2000-11-11
NO20011409D0 (no) 2001-03-20
BG105445A (en) 2001-12-29
PA8482001A1 (es) 2000-05-24
BR9913975A (pt) 2001-06-19
CA2344670A1 (en) 2000-03-30
KR20010075222A (ko) 2001-08-09
AR029739A1 (es) 2003-07-16
MA26690A1 (fr) 2004-12-20
EP1115402A1 (en) 2001-07-18
TR200101357T2 (tr) 2001-08-21
CO5140075A1 (es) 2002-03-22
EE200100179A (et) 2002-10-15
CN1319013A (zh) 2001-10-24
SK3592001A3 (en) 2001-12-03
HUP0103691A2 (hu) 2002-02-28
HUP0103691A3 (en) 2003-01-28
NO20011409L (no) 2001-03-28
US20010034347A1 (en) 2001-10-25
IS5852A (is) 2001-02-20
GEP20033081B (en) 2003-10-27
GT199900154A (es) 2001-03-06
US6608064B2 (en) 2003-08-19
DZ2894A1 (fr) 2003-12-15
HRP20010209A2 (en) 2002-04-30
AP1456A (en) 2005-09-30
KR20030088512A (ko) 2003-11-19
TW518225B (en) 2003-01-21
EA200100204A1 (ru) 2001-08-27
NZ509855A (en) 2003-04-29
WO2000016777A1 (en) 2000-03-30
KR20040054752A (ko) 2004-06-25
IL141507A0 (en) 2002-03-10
KR100468340B1 (ko) 2005-01-27
OA11653A (en) 2004-12-08
AU5383199A (en) 2000-04-10
EA200301063A1 (ru) 2004-12-30
TR200402083T2 (tr) 2004-10-21
YU21701A (sh) 2004-07-15
PL346904A1 (en) 2002-03-11

Similar Documents

Publication Publication Date Title
PE20001084A1 (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas
EA200100058A1 (ru) 4-бензилпиперидиналкилсульфоксидные гетероциклические соединения и их применение в качестве подтип-избирательных антагонистов nmda-рецепторов
EA200100553A1 (ru) Замещенные бициклические производные, полезные в качестве противораковых агентов
EA200400589A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
EA200100284A1 (ru) Агонисты 5ht1 рецепторов и метоклопрамид для лечения мигрени
PE20011114A1 (es) Decahidro-isoquinolinas
ATE309249T1 (de) Chemokin rezeptor antagonisten und verwndung
PE20001583A1 (es) Derivados de la 1-arenosulfonil-2-arilo-pirrolidina y de la piperidina
PE20050484A1 (es) Composicion farmaceutica de liberacion sostenida
ATE225349T1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
HUP0103203A2 (hu) Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények
SE0102055D0 (sv) New Compounds
PE79599A1 (es) Derivados de 5'-desoxicitidina
EA200000023A1 (ru) Производные 2-(-4-арил или гетероарил-пиперазин-1-илметил) -1h-индола
BR0212353A (pt) Composto, composição farmacêutica, e, uso de um composto
CO5460266A1 (es) Novedosos analogos de la somatostatina
HUP0203622A2 (hu) Biciklusos vazopresszin agonisták és ezeket tartalmazó gyógyszerkészítmények
AR024840A1 (es) Compuestos de 5ht1 para terapia antidepresiva; composiciones farmaceuticas y su uso en la preparacion de medicamentos.
NO173869C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,7-kondenserte 1h-indol-2-carboxylsre-n-(1,4-benzodiazepin-3-yl)-amider
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
DE60329607D1 (de) Sich als therapeutische mittel eignende arylalkylindole mit affinität für den serotoninrezeptor, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten
EA200000198A1 (ru) 2-ациламинопропанамины в качестве антагонистов рецепторов тахикининов
DE69819742D1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten
BR0112957A (pt) Composto, método de tratamento, uso de um composto, e, composição farmacêutica
DE68919280D1 (de) Alpha-adrenergische Rezeptorantagonisten.

Legal Events

Date Code Title Description
FC Refusal